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Animal and human studies have demonstrated that chronic activation of renal
sympathetic nerves is critical in the pathogenesis and perpetuation of treatment-resistant
hypertension. Bilateral renal denervation has emerged as a safe and effective,
non-pharmacological treatment for resistant hypertension that involves the selective
ablation of efferent and afferent renal nerves to lower blood pressure. However, the
most recent and largest randomized controlled trial failed to confirm the primacy of
renal denervation over a sham procedure, prompting widespread re-evaluation of the
therapy’s efficacy. Disrupting renal afferent sympathetic signaling to the hypothalamus
with renal denervation lowers central sympathetic tone, which has the potential to confer
additional clinical benefits beyond blood pressure control. Specifically, there has been
substantial interest in the use of renal denervation as either a primary or adjunct therapy
in pathological conditions characterized by central sympathetic overactivity such as
renal disease, heart failure and metabolic-associated disorders. Recent findings from
pre-clinical and proof-of-concept studies appear promising with renal denervation shown
to confer cardiovascular and metabolic benefits, largely independent of changes in
blood pressure. This review explores the pathological rationale for targeting sympathetic
renal nerves for blood pressure control. Latest developments in renal nerve ablation
modalities designed to improve procedural success are discussed along with prospective
findings on the efficacy of renal denervation to lower blood pressure in treatment-resistant
hypertensive patients. Preliminary evidence in support of renal denervation as a possible
therapeutic option in disease states characterized by central sympathetic overactivity is
also presented.
Keywords: sympathetic overactivity, renal denervation, blood pressure, resistant hypertension, cardiovascular
disease, renal nerve activity
Introduction
Treatment-resistant hypertension (rHTN) is a clinically important condition that is associated with
increased cardiovascular morbidity and mortality risk (Daugherty et al., 2012; Irvin et al., 2014).
Defined by the failure to achieve target blood pressure (BP) despite taking ≥3 antihypertensive
medications at optimal doses, rHTN is estimated to affect 8−10% of all hypertensive adults
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(Persell, 2011; De La Sierra et al., 2011). Poor adherence to
pharmacotherapy is ubiquitous in this patient cohort hindering
efforts for timely and consistent BP management (Jung et al.,
2013), which has caused some clinicians to question whether
rHTN really exists or is a case of difficult-to-treat hypertension.
Despite the controversy, there is compelling evidence that
chronic sympathetic outflow to and from the kidneys is involved
in the pathophysiology of rHTN (Esler et al., 1989; Schlaich et al.,
2004; Smith et al., 2004).
The emergence of catheter-based renal denervation (RDN)- a
minimally invasive procedure used to ablate renal sympathetic
nerves- has marked a paradigm shift in the therapeutic
management of rHTN. The long-term safety and efficacy of
RDN to control BP has principally been evidenced by open-
label studies. In the last 12-months, several rigorously designed,
randomized controlled trials have brought into question the
efficacy of RDN to treat rHTN. Specifically, data from the
Symplicity HTN-3 study failed to show the primacy of RDN in
lowering BP compared to a sham-procedure in rHTN patients
(Bhatt et al., 2014).
In addition to rHTN, sympathetic overactivity is a cardinal
feature of several pathological conditions including renal disease,
heart failure, left-ventricular hypertrophy, insulin resistance,
and sleep apnea. The ability of RDN to alter renal afferent
signaling and reduce whole body sympathetic nerve activity in
these disease states is currently being explored in a number of
preclinical and clinical studies with promising results.
This review will we focus on the importance of renal
sympathetic nerves in the pathophysiology of rHTN,
technological advancements in ablation modalities for RDN
and latest prospective clinical findings. Novel therapeutic
applications for RDN beyond BP control will also be discussed
along with several critical issues that must be addressed for
research going forward.
Renal Nerves: An Important Target for
Blood Pressure Control
The kidneys are connected to the autonomic nervous system via
a dense, neuronal network of post-ganglionic sympathetic nerve
fibers located within the adventitia of the renal artery (Dibona,
2005). Renal efferent motor fibers innervate all parts of the renal
vasculature, tubules, and juxtaglomerular apparatus (Barajas,
1978); while afferent sensory nerves are located principally in the
renal pelvic wall and serve to connect the kidneys with autonomic
centers in the central nervous system (Kopp, 1992).
Animal (Dibona and Kopp, 1997) and human (Esler,
2000) studies suggest chronic activation of renal sympathetic
nerves is important in the pathogenesis and perpetuation of
essential hypertension as well as other pathological conditions
including heart failure, chronic kidney disease, and diabetes
(see review Malpas, 2010). As highlighted in Figure 1, sustained
efferent sympathetic outflow to the kidneys (via peripheral
and central sensory inputs) elevates BP by altering renal
vascular resistance (Kirchheim et al., 1989), stimulating renin
release from juxaglomerular granular cells (Zanchetti, 1977)
and increasing tubular sodium and water reabsorption (Bell-
Reuss et al., 1976). Excitatory reflexes originating from afferent
renal nerves in the kidney can also contribute to development
of hypertension, particularly rHTN (Hering et al., 2014).
Under normal physiological conditions, changes in hydrostatic
pressures or chemical composition of the renal environment
activate sensory afferent renal nerves to stimulate a centrally-
mediated decrease in efferent renal sympathetic outflow via an
inhibitory feedback mechanism, known as the renorenal reflex
response.
Pathological activation of renal sensory afferent nerve
fibers through renal ischemia, injury or elevated adenosine
concentrations (Esler, 2010), can alter the activity of central
integrative neuronal circuits involved in cardiovascular
homeostasis and shift the renorenal reflex response from
inhibitory to excitatory. The consequence is an increase in
central efferent sympathetic outflow to the kidneys and to other
highly innervated organs (such as the heart and vasculature)
initiating the development and/or maintenance of hypertension
and other pathological conditions.
The application of radiofrequency energy to ablate renal
nerves in the adventitia can reduce efferent renal sympathetic
activity [as evidenced by a reduction in noradrenaline spillover
in the kidney (Krum et al., 2009)] to promote urinary sodium
excretion and BP reduction; while the ablation of afferent renal
sympathetic nerves lowers BP via the inhibition of central
sympathetic outflow (Schlaich et al., 2009a).
Changing Face of Renal Denervation:
Latest Developments in Device-based
Nerve Ablation
Concomitant with the refinement of radiofrequency-based
catheter ablation systems, there has been an emergence of novel
treatment modalities that use highly differentiated approaches
(i.e., ultrasonic nerve, pharmacological, and cryoablation)
to ablate renal sympathetic nerves. These next-generation
RDN systems may potentially offer several clinical advantages
to radiofrequency-based modalities namely the ability to
deliver energy circumferentially and penetrate deeper into the
adventitia to optimize neural damage, while preserving artery
integrity.
Intravascular and fully non-invasive ultrasound nerve
ablation modalities have undergone extensive clinical
investigation in the last 12–18 months (refer Table 1).
Intravascular ultrasound ablation modalities use transducer-
based catheters to deliver high-intensity, non-focused ultrasonic
emissions (rapid mechanical oscillations) to renal nerves at a
depth range of 0.5–10mm. The latest iteration of the ReCor
Percutaneous Renal Denervation System (the RADIANCE™
catheter) uses a novel radial access approach to deliver ultrasonic
waves to the renal adventitia, promoting minimal invasiveness
to the patient. The therapeutic intra-vascular ultrasound
(TIVUS™) catheter system (Cardiosonic Ltd, Tel Aviv, Israel)
similarly delivers ultrasonic waves to the renal adventitia but
in the absence of endoluminal surface contact, preserving the
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FIGURE 1 | Schematic illustration of the role of increased renal
efferent sympathetic outflow and increased renal afferent sensory
signaling in the pathophysiology of hypertension and other
cardiovascular, renal, and metabolic disease states. ERSNA,
efferent renal sympathetic nerve activity; ARSNA, afferent renal
sympathetic nerve activity; RAAS, renin–angiotensin–aldosterone system;
LVH, left ventricular hypertrophy; LV, left ventricular; CNS, central
nervous system.
integrity of the artery. Results from first-in-man studies highlight
the efficacy and safety of these latest modalities to reduce BP
short-term (Jonas et al., 2014; Shetty et al., 2014; Daemen and
Van Mieghem, 2015) with prospective, multi-center, clinical
studies currently underway.
The Surround Sound Hypertension Therapy System (Kona
Medical, Washington, USA) is the only fully external ultrasound-
based RDN system being investigated as an adjunct therapy to
medication in rHTN patients. Circumferential nerve ablation
is achieved using externally focused, low-frequency ultrasonic
waves delivered to the renal adventitia via an ultrasound
imaging transducer. Initial data from a series of small clinical
trials (WAVE I and WAVE II) found that 81% of patients
(total n = 41 across the two studies) experienced clinically
significant reductions in office SBP (≥10mmHg) at 6-months
follow-up with no serious adverse events reported (Neuzil
et al., 2014; Ormiston et al., 2014). Primary outcomes from a
multi-center randomized, sham-controlled, double-blinded trial
involving 132 subjects (WAVE IV) are expected to be released
later this year. The findings will be of interest as only the
second, sham-controlled clinical trial in rHTN patients and
first to include a treatment arm of patients who have failed
radiofrequency RDN modalities (Daemen and Van Mieghem,
2015).
Clinical Findings Update: Where is the
Evidence-base on Renal Denervation?
In the past 12-months there have been 5 prospective, randomized
controlled trials that have reported either a modest or no effect
of RDN on BP reduction in patients with rHTN (Bhatt et al.,
2014; Fadl Elmula et al., 2014; Azizi et al., 2015; Desch et al.,
2015; Rosa et al., 2015). Of most relevance is the Symplicity
HTN-3 study, the largest and most rigorously designed trial to
date, which failed to meet its primary efficacy endpoint (mean
6-month change in office SBP) (Bhatt et al., 2014). Previously,
the only prospective trial to compare the BP lowering effects of
RDN to usual care had been the open-label Symplicity HTN-
2 Study (Esler et al., 2010), which reported a significant office
BP reduction of −32/−12mmHg at 6-months following RDN.
The Symplicity HTN-2 study is recognized as having several
limitations, the most notable being the use of office BP over 24-h
ambulatory BP monitoring to assess the efficacy of RDN and the
absence of a blinded control drug adherence monitoring in the
study.
As the first randomized, double-blinded, sham-controlled
trial, the Symplicity HTN-3 study was expected to provide
the definitive statement on the superiority of RDN in the
treatment of severe rHTN (Bhatt et al., 2014). A total of 535
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TABLE 1 | Overview of emerging intravascular and non-invasive ultrasound modalities for circumferential renal nerve ablation.
Product name RDN modality Description/feature CE mark Clinical trial data Ongoing/planned trials
ReCor RADIANCE catheter
system
Intravascular
ultrasound nerve
ablation
Cylindrical catheter advanced
into renal artery via radial access.
3 unfocused, ultrasounic
emissions delivered bilaterally.
Yes First-in-man study (n = 2) Prospective, single-arm,
open-label study (REALISE
Trial; n = 20)- ongoing not
recruiting patients.
At 3-mo follow-up mean
decline in office BP
(−40/−29mmHg) and
24-h ambulatory BP
(−11/−8mmHg).
Cardiosonic TIVIS catheter
system
Intravascular
ultrasound nerve
ablation
Catheter delivers high-frequency,
high-intensity directional
ultrasound emissions.
Radiopaque tip positions
catheter using fluoroscopic
guidance. No endoluminal
surface contact is required.
Yes First-in-man study (TIVUS I;
n = 18 with rHTN).
Prospective,
non-randomized,
single-arm, open label
study. Mean decline in
office BP at 1-mo
(−28/−10mmHg; n = 18)
and 3-mo follow-up
(−25/−10mmHg; n = 16).
Prospective, multicenter,
non-randomized,
single-arm, open-label
clinical study using system
next generation
Multidirectional Catheter
TIVUS™ (TIVUS II). Study
will include treatment arm
for patients who have failed
radio-frequency RDN. To
date 6 patients have been
enrolled in TIVUS™ II –
ongoing and recruiting
patients.
Sound Interventions
SOUND 360 catheter
system
Intravascular
ultrasound nerve
ablation
Cylindrical transducer encased in
a non-cylindrical, non-occlusive
balloon delivers therapeutic
ultrasound at specific dosimetry.
2 unfocused ultrasonic
emissions delivered bilaterally.
No First-in-man study
(SOUND-ITV; n = 10 with
rHTN). Mean decline in
office BP
(−25.6/−12.5mmHg) and
24-h ambulatory BP
(−23.1/−11.9mmHg) at
3-mo follow-up. 3 patients
developed groin
hematomas not requiring
intervention.
Nil
Kona Medical Surround
Sound Hypertension
Therapy system
Non-invasive
ultrasound nerve
ablation
Externally focused, low
frequency ultrasonic emissions
delivered bilaterally to the renal
adventitia.
No First-in-man study (WAVE I;
n = 24)
Multi-center, randomized,
sham-controlled,
double-blind trial (WAVE IV;
target n = 132). Study will
include treatment arm for
patients who have failed
alternate forms of
RDN-ongoing and
recruiting patients.
At 6-mo follow-up, mean
−27mmHg decline in
office SBP.
WAVE II trial: n = 13 with
rHTN. At 6-week follow-up
(n = 8), mean −18mmHg
decline in office SBP, no
decline in office DBP. No
serious adverse events.
WAVE III trial- completed,
results not yet disclosed.
rHTN, resistant hypertension.
patients were assigned in a 2:1 ratio to receive either the
RDN or sham-procedure. Treatment rHTN was confirmed at
baseline using 24-h ambulatory BPmonitoring following 2-weeks
of stable, maximally tolerated doses of ≥3 antihypertensive
medications of complementary classes (including a diuretic).
The 6-month follow-up data revealed significant office BP
reductions in both treatment groups (RDN:−14.1/6.8mmHg vs.
SHAM: −11.7/4.8mmHg; both p < 0.001). However, between-
treatment differences in office BP reduction at 6-months were
not significant (−2.4/2.0mmHg; P = 0.26). Concomitantly, no
superior treatment effect of RDN over the sham-procedure for
mean change in 24-h (p = 0.98), daytime (p = 0.52), or night-
time (p = 0.06) ambulatory SBP was observed (Bakris et al.,
2014).
Clearly, the failure of Symplicity HTN-3 to show a clear-
cut superiority of RDN over the sham-procedure in lowering
BP (modest ∼2mmHg SBP reduction only) was disappointing,
but contemplated by some (Howard et al., 2013). Evidence from
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a recent meta-analysis that combined office and ambulatory
BP data from 10 European centers predicted similar, modest
6-month BP reductions following RDN and large variability
in patient’s BP responsiveness (Persu et al., 2014). A number
caveats with the Symplicity HTN-3 study design have since
been identified that may well account for some of the neutral
findings. Specifically, despite the inclusion of a sham-procedure,
themajority of interventional cardiologists were inexperienced in
performing the procedure (one third performed one procedure
only), only 6% of patients received bilateral circumferential
ablation (as per protocol) with energy preferentially applied
to the proximal portion of the renal artery, renal and total
body noradrenaline spillover testing (measure of renal efferent
activity and central sympathetic drive via renal afferent pathway
respectively) was not performed, and patient’s medication
regime prior to testing at baseline and 6-months was not
stable.
In the aftermath of the Symplicity HTN-3 study
announcement, 3 rigorously designed, prospective, open-label
randomized controlled trials using the same single-electrode
Symplicity radiofrequency catheter system (Medtronic Inc,
Minnesota, USA) have been published (Fadl Elmula et al.,
2014; Azizi et al., 2015; Rosa et al., 2015). As highlighted in
Table 2, two of the studies showed intensive pharmacotherapy
to be equally effective (Fadl Elmula et al., 2014; Rosa et al.,
2015) to RDN in lowering BP in patients with true rHTN,
highlighting the ability of RDN to lower BP at least to the
extent of additional pharmacologic treatment. The third
study (DENER-HTN) comparing RDN in combination with
standardized, stepped-care antihypertensive treatment (SSAHT)
observed a modest, albeit significant reduction in 6-month
daytime SBP [adjusted mean difference of −5.9mmHg (95%CI:
−11.3, −0.5); p = 0.03] compared to SSAHT alone (Azizi et al.,
2015).
Despite their smaller cohort sizes, a major strength of these
latest studies was the careful selection of patients with true
treatment rHTN. Patients were only recruited if they had
elevated ambulatory daytime systolic BP after witnessed intake
(Fadl Elmula et al., 2014) or quantitative plasma/urine levels
(Azizi et al., 2015; Rosa et al., 2015) confirmation of prescribed
antihypertensive medications. The absence of a sham-procedure
in favor of standardized pharmacological intervention in the
studies was also compensated by the use of ambulatory BP
monitoring to assess the efficacy of RDN (which is preferential
to the use of office BP) in combination with drug adherence
monitoring. Such measures help to minimize the potential over-
inflation of treatment-effects caused by white coat hypertension
or the Hawthorn effect, which is a criticism of the Symplicity
HTN-3 study.
Preliminary data from a recent study using the Symplicity-
FLEX catheter is somewhat more encouraging for RDN (Desch
et al., 2015). The smaller study (n = 71) designed to
emulate the Symplicity HTN-3 in patients with mild refractory
hypertension (defined as daytime systolic BP of 135−149mmHg
and/or diastolic BP of 90−94mmHg on ≥3 antihypertensive
medications) found that in the per-protocol analyses, those who
underwent RDN (n = 29) experienced a significant reduction
in mean 24-h and daytime systolic BP at 6-months follow-
up compared to patients treated with a sham-procedure (n =
34). On average, RDN reduced 24-h and daytime systolic BP
by −4.8mmHg (mean ± SD: −8.3 ± 8.9mmHg vs. −3.5 ±
9.5mmHg; p = 0.04) and −6.2mmHg (mean ± SD: −9.9 ±
9.0mmHg vs. −3.7 ± 9.9mmHg; p = 0.01), respectively. In
the intention-to-treat analyses (primary outcome) the significant
treatment-effects observed in the per-protocol analyses group
were attenuated (p = 0.15). The inclusion of patients who should
a priori not have been eligible for the study has been suggested as
a possible explanation (Desch et al., 2015).
Beyond Blood Pressure Control: Other
Therapeutic Uses of Renal Denervation
The localized effect of disrupting renal afferent signaling suggests
RDN may offer distinct clinical benefits beyond BP control
in pathological conditions characterized by central sympathetic
overactivity. Specifically, there has been intense interest in the
application of RDN in patients with renal disease, heart failure,
and metabolic disorders (Mahfoud et al., 2011).
Chronic Kidney Disease/Dialysis
Excessive sympathetic nerve activity is a hallmark of both
chronic kidney disease (CKD) and end-stage renal disease
(ESRD). In CKD patients, augmented sympathetic tone is present
in the early clinical stages of the disease and increases with
disease progression (Grassi et al., 2011). Animal (Campese
et al., 1995) and human (Converse et al., 1992; Grassi et al.,
2011) studies have identified afferent signaling from diseased
kidneys as playing a critical role in the progression of renal
function decline. Indeed, in hypertensive patients, increased
muscle sympathetic nerve activity is strongly associated with a
decline in estimated glomerular filtration rate (eGFR) (Grassi
et al., 2011). Bilateral nephrectomy is also shown to normalize
elevated muscle sympathetic nerve activity in non-dialysis ESRD
patients (Converse et al., 1992).
Despite the known importance of BP control for optimal
renal function (Bakris et al., 2000) and mounting evidence that
RDN does not induce structural or functional renal damage in
hypertensive patients (Mahfoud et al., 2012; Dorr et al., 2013),
international consensus states the procedure remain limited to
patients with preserved renal indices. Hering et al. first reported
on the efficacy and short-term safety of RDN in 15 moderate-
to-severe CKD (mean creatinine-based eGFR 31.2mL/min/1.73
m2) patients with rHTN (Hering et al., 2012). The study
showed RDN safely reduced peripheral arterial stiffness and
office BP while preserving renal blood flow, electrolytes and
eGFR at 6-months follow-up. Pilot data from 24 predominantly
stage 2 CKD patients (mean eGRF 64.4mL/min/1.73 m2) with
treatment rHTN (Kiuchi et al., 2013) showed a similar beneficial
effect on 24-h ambulatory BP (mean reduction from baseline
−19/−7mmHg; p < 0.001) that was accompanied by short-term
improvements in renal function. Compared to baseline, patients
reported significantly higher eGFR and reduced urine albumin:
creatinine ratio and serum creatinine (all P < 0.001) at 6-months
follow-up. The conflicting short-term effects on eGRF reported
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TABLE 2 | Randomised controlled trials using renal nerve ablation in the treatment of resistant hypertension in the last 12-months.
Study ID Symplicity HNT-3
(Bhatt and Bakris, 2014)
PRAGUE-15 study
(Rosa et al., 2015)
DENER-HTN trial
(Azizi et al., 2015)
Symplicity FLEX study
(Desch et al., 2015)
OSLO RDN study
(Fadl Elmula et al., 2014)
Study
design
Prospective, single-blind
multi-center RCT with 2:1
treatment (RDN v SHAM)
randomization
Prospective, open-label,
multi-center RCT with 1:1
treatment randomization
Prospective, single-blind,
multi-center RCT with 1:1
treatment randomization
Prospective, open-label
RCT with 1:1 treatment
randomization
Prospective, open-label
RCT with 1:1 treatment
randomization
Control Sham-procedure (renal
angiography)
Intensive pharmacotherapy
with spironolactone
Standardized stepped-care
antihypertensive treatment
(SSAHT)
Sham-procedure (renal
angiography)
Antihypertensive drug
adjustment
Patient
Cohort
RDN: n = 364 RDN: n = 52 RDN + SSAHT: n = 53 RDN: n = 35 RDN: n = 9
Mean age: 58 ± 10 years Mean age: 56 ± 12 years Mean age: 55 ± 11 years Mean age: 65 ± 8 years Mean age: 57 ± 11 years
Number of BP medications:
5.1± 1.4
Mean office
SBP:159 ± 19mmHg
Mean office
SBP:159 ± 23mmHg
Mean daytime
SBP:144 ± 5mmHg
Mean office
SBP:156 ± 13mmHg
SHAM: n=171 Number of BP medications:
5.1± 1.2
SSAHT: n=53 Number of BP medications:
4.4± 1.3
Number of BP medications:
5.1± 1.6
Mean age: 56 ± 11 years PHAR: n=54 Mean age: 55 ± 10 years SHAM: n=36 PHAR: n=10
Number of BP medications:
5.2± 1.4
Mean age: 59 ± 9 years Mean office
SBP:156 ± 22mmHg
Mean age: 57 ± 9 years Mean age: 63 ± 5 years
Mean office
SBP:155 ± 17mmHg
Mean daytime
SBP:143 ± 5mmHg
Mean office
SBP:160 ± 12mmHg
Number of BP medications:
5.4 ± 1.2
Number of BP medications:
4.3 ± 1.3
Number of BP medications:
5.0 ± 1.2
RDN
Modality
Symplicity single-electrode
radiofrequency catheter
system (Medtronic Inc.)
Symplicity single-electrode
radiofrequency catheter
system (Medtronic Inc.)
Symplicity single-electrode
radiofrequency catheter
system (Medtronic Inc.)
Symplicity FLEX
multi-electrode
radiofrequency catheter
system (Medtronic Inc.)
Symplicity single-electrode
radiofrequency catheter
system (Medtronic Inc.)
Drug
Adherence
Patient diary Plasma drug concentration 8-item Morisky Medication
Adherence Scale
Patient diary Witnessed intake
Primary
Outcome
Change in 6-mo office SBP Changes in 6-mo 24-h
ambulatory BP
Change in 6-mo daytime
ambulatory SBP
Change in 6-mo 24-h
ambulatory SBP
(intention-to-treat)
Change in 6-mo office SBP
Secondary
Outcomes
Change in 6-mo 24-h
ambulatory SBP
1-year spironolactone
(PHAR) or medical (RDN)
effects
Change in 6-mo ambulatory,
home and office BP
measures; eGFR; incidence
of adverse events;
Change in 6-mo 24-h
ambulatory DBP and mean
ambulatory BP
(intention-to-treat); change
in 24-h ambulatory SBP
(per-protocol)
Change in 3-mo and 6-mo
daytime ambulatory BP
Results Mean change in 6-mo office
SBP
Mean change in 6-mo 24-h
ambulatory SBP:
Mean change in 6-mo
daytime ambulatory SBP:
Mean change in 6-mo 24-h
ambulatory SBP:
Office SBP at baseline and
6-mo:
RDN:
−14.13± 23.93mmHg
RDN: −8.6mmHg
(−11.8, −5.3)
RDN + SSAHT:
−15.8mmHg
(−19.7, −11.9)
RDN: −7.0mmHg
(−10.8, −3.2)
RDN: 156 ± 13 vs.
148 ± 7mmHg (p = 0.42)
SHAM:
−11.74± 25.94mmHg
PHAR: −8.1mmHg
(−12.7, −3.4)
SSAHT: −9.9mmHg
(−13.6, −6.2)
SHAM: −3.5mmHg
(−6.7, −0.2)
SHAM: 160 ± 14 vs.
132 ± 10mmHg
(both P < 0.001)
No treatment differences for
change in 6-mo office SBP
(p = 0.26) or 24-h
ambulatory SBP (p = 0.98)
(both P = 0.001)
No treatment differences for
change in 6-mo 24-h,
daytime or night-time
ambulatory BP (all P > 0.36)
Significant treatment
difference for change in
6-mo daytime SBP
(p = 0.03) in favor of RDN
group
No treatment difference for
change in 6-mo 24-h
ambulatory SBP (p = 0.15)
Per-protocol: significant
treatment difference for
change in 6-mo 24-h
ambulatory SBP (p = 0.042)
in favor of RDN group
(P < 0.0005)
Significant treatment
differences for change in
6-mo office SBP (p = 0.002)
and office DBP (p = 0.004)
in favor of PHAR group
(Continued)
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TABLE 2 | Continued
Study ID Symplicity HNT-3
(Bhatt and Bakris, 2014)
PRAGUE-15 study
(Rosa et al., 2015)
DENER-HTN trial
(Azizi et al., 2015)
Symplicity FLEX study
(Desch et al., 2015)
OSLO RDN study
(Fadl Elmula et al., 2014)
Conclusion BP lowering effects of RDN
is comparable to a
sham-operation rHTN in
patients with.
BP lowering effects of RDN
is comparable to intensive
pharmacotherapy in
patients with true rHTN.
BP lowering effects of
RDN + SSAHT is superior
to SSAHT alone in patients
with rHTN.
BP lowering effects of RDN
is comparable to a
sham-operation in patients
with rHTN.
BP lowering effects of
intensified pharmacological
therapy is superior to RDN
in patients with true rHTN.
Data presented as mean ± SD or mean [95%CI]. RCT, randomized controlled trial; RDN, renal denervation; SHAM = invasive sham-procedure; PHAR, pharmacological treatment;
rHTN, resistant hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; mo, month.
between these two aforementioned pilot studies, suggests RDN
may afford the greatest clinical benefit to patients in the early
stages of CKD who have not yet undergone extensive vascular
remodeling.
Two recent prospective longitudinal studies have reported
sustained benefits in renal function parameters following RDN
(Kiuchi et al., 2014; Ott et al., 2015). Kiuchi et al. observed of 27
CKD patients with rHTN that underwent RDN, those (n = 22)
who achieved BP control (defined as office SBP <140mmHg) at
12-months follow-up also reported a significantly higher eGRF
(mean ± SD difference 18.54 ± 8.15ml/min/1.73 m2; p =
0.03). Furthermore, improvements in office diastolic BP, serum
creatinine and ACR were only observed at 12-months follow-up
in patients who achieved BP control (P < 0.05 for all) (Kiuchi
et al., 2014).
In a separate multi-center observational study (Ott et al.,
2015), RDN was prospectively shown to reduce mean 24-h
ambulatory BP (mean ± SD; 9 ± 14/4 ± 7mmHg; P < 0.02)
and improve mean eGFR by 1.5 ± 10ml/min/1.73 m2 (p =
0.009) after 12-months in 27 rHTN patients with moderate-to-
severe CKD. The efficacy of RDN to preserve renal function was
evidenced by retrospective analyses showing patients experienced
an average decline in eGFR of −4.8 ± 3.8ml/min/1.73 m2 per
year prior to the RDN procedure. Interestingly, the magnitude
of change in 24-h ambulatory systolic BP at 12-months was
not shown to predict change in eGFR. This contrasts with
Kiuchi et al.’s study (Kiuchi et al., 2014) and suggests RDN may
attenuate renal function decline via mechanisms unrelated to BP.
Importantly, neither procedural complications nor evidence of
acute kidney injury following RDN was reported in patients.
Central sympathetic activity present in ESRD patients is
driven principally by afferent renal nerve signaling from the
diseased native kidneys (Converse et al., 1992). To date, the use
of RDN to reduce increased cardiovascular mortality in ESRD
patients with renal hypertension has been explored in a limited
number of clinical studies (Schlaich et al., 2009b; Spinelli et al.,
2014). In a proof-of-concept study of 9 patients with ESRD and
hypertension, RDN resulted in sustained reductions in office
SBP of −18, −16, and −28mmHg at 3−, 6−, and 12-months,
respectively (Schlaich et al., 2009b). Two patients (n = 2)
who underwent additional measures of sympathetic activity at
3-months, also displayed reductions in muscle sympathetic nerve
activity, and renal and whole body noradrenaline release. With
respect to safety, only 2 patients developed perioperative femoral
pseudo-aneurysms that were resolved without further sequelae.
Findings from the pilot trial are supported by an elegant case
series involving four patients (age range: 22–65 years) with ESRD
and difficult anatomy (renal arteries < 4mm) (Spinelli et al.,
2014), which reported a mean reduction in 24-h ambulatory BP
of −36/−16mmHg at 12-months follow-up. With the exception
of notches detected on the final angiogram, no other procedure
related complications were reported. Larger, randomized
controlled clinical trials are planned or currently ongoing
to substantiate the seminal findings that RDN is a safe and
efficacious therapeutic approach to both lower BP and regulate
sympathetic activity in patients with impaired kidney function.
Chronic Heart Failure
Chronic heart failure (CHF) patients often exhibit renal
dysfunction with augmented sympathetic tone (Hasking et al.,
1986). Renal and cardiac noradrenaline spillover is a stronger
predictor of mortality (Hasking et al., 1986; Petersson et al.,
2005) than whole-body noradrenaline spillover in CHF patients
suggesting chronic renal afferent nerve signaling is involved in
the maintenance and progression of the pathological state.
Two small-scale trials assessing the potential benefits of
RDN have been undertaken in CHF patients (Davies et al.,
2013). The REACH pilot study evaluated the safety of RDN
in 7 normotensive patients with CHF (class III–IV) and mean
ejection fraction of 45% (Davies et al., 2013). At 6-months, all
patients showed an improvement in their functional capacity
(as assessed by a 6-min walk test) and overall quality of life.
Importantly, no procedural complications or symptomatic
adverse effects were reported and renal hemodynamics and
function were also preserved.
In a larger observational study (OLOMOUC 1 Study)
involving 51 patients with advanced CHF (mean ejection
fraction 25%), RDN was associated with improved ventricular
systolic function compared to standardized drug therapy (beta-
blockers, ACE inhibitors or ARBs and diuretics) (Taborsky et al.,
2012). Of the 26 patients randomized to RDN, left ventricular
ejection fraction improved by an average of 6% at 12-months
follow-up (mean ± SD: 25 ± 12% vs. 31 ± 14%; p < 0.01).
No change was reported in the 25 patients randomized to
standardized drug therapy (p = 0.36). Patients in the RDN
group also reported significant reductions in heart rate and
NT-pro brain natriuretic peptide levels and twice as fewer
hospitalisations (31 vs. 72%; p < 0.001) during follow-up. Both
treatments were shown to preserved patients renal function (as
measured by eGFR; p = 0.55).
The stabilizing effect on RDN on heart failure progression
is currently being investigated in several larger, randomized
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controlled trials. Studies in diastolic heart failure patients are
also ongoing. Specifically, the DIASTOLE study will usemagnetic
resonance imaging to assess the efficacy of RDN to improve
diastolic functional parameters in a multicenter-randomized
controlled trial of 60 heart failure patients with preserved ejection
fraction (Verloop et al., 2013).
Left Ventricular Hypertrophy
Left ventricular hypertrophy (LVH) is an indicator of end-organ
damage in arterial hypertension and is associated with increased
cardiovascular morbidity and mortality risk, independent of BP
(Ruilope and Schmieder, 2008; Bombelli et al., 2009). Chronic
sympathetic nerve activity is shown to mediate hypertension-
induced cardiac remodeling (Perlini et al., 2005). In hypertensive
adults, cardiac noradrenaline spillover is positively related to LV
mass index, suggesting a direct relationship between increased
cardiac sympathetic activity in the development of LVH (Schlaich
et al., 2003).
Two echocardiographic pilot studies have reported beneficial
effects of RDN on measures of cardiac function and structure
(Brandt et al., 2012; Schirmer et al., 2014). In 46 patients with
rHTN, RDN was shown to significantly reduce LV mass (by
17%) and interventricular septum thickness (by −1.6mm) at
6-months follow-up (both p < 0.001). Improvements in LV
ejection fraction, LV end-systolic volume, diastolic LV filling
pressures and isovolumic relation time were also observed (all
p < 0.006). With the exception of LV mass and left atrial
size, which was higher at 6-months follow-up compared to
RDN patients, no other significant changes were observed in
the control patients (n = 18). The effect of RDN on LV
mass regression and diastolic function, while most prominent in
patients who displayed the greatest reduction in systolic BP, was
not exclusively associated with 6-month BP changes, suggesting
RDN exerts effects on cardiac remodeling independent of BP.
Schirmer et al. similarly reported in 66 overweight patients with
rHTN a reduction in LV mass, improved diastolic function and
increased vascular compliance at 6-months following RDN (all
P < 0.001) (Schirmer et al., 2014). Compared to baseline,
reductions in office BP (mean reduction −22/−10mmHg) and
heart rate (mean reduction −7 bpm) were also observed (both
p < 0.001). With the exception of vascular compliance, which
was directly correlated with BP reduction (r2 = 0.29, p < 0.001),
the degree of LV mass regression or diastolic improvement
reported post-RDN was not dependent on the magnitude of
reduction in BP or heart rate.
A recent prospective multi-center, blinded study using
cardiac magnetic resonance imaging (a more reliable measure of
cardiac function and morphology), confirms the aforementioned
echocardiographic findings that RDN reduces LV mass
regression and improves LV ejection fraction largely independent
of the significant changes in BP (Mahfoud et al., 2014). Compared
to 17 patients who received medical treatment only, 55 patients
with rHTN treated with RDN reported a significant 7.1%
reduction in LV mass (mean ± SD: 46.3 ± 13.6 vs. 43.0 ±
12.6 g/m1.7; P < 0.001) and 3.4% improvement in ejection
fraction (mean ± SD: 55.7 ± 11.1 vs. 57.6 ± 9.3%; P = 0.048)
at 6-months follow-up. Importantly, LV mass was reduced in
those patients who did not show significant clinical reductions
in systolic BP at 6-months (defined as systolic BP reduction <
10mmHg). In a sub-group of patients (n = 19) with markedly
reduced systolic LV ejection fraction (defined as <50%) at
baseline, the effect of RDN was even more pronounced resulting
in a 7.3% improvement in LV ejection fraction; P < 0.001) at
6-months. Left ventricular wall stress, defined as a function of
chamber size and configuration, thickness of the ventricular
wall and intraventricular pressure was also significantly reduced
following RDN at 6-months (p = 0.03). No changes in any
cardiac parameters were reported in the control group.
Given the current findings support RDN having a prognostic
benefit on LVH regression in resistant hypertensive patients who
are at heighten risk for heart failure, larger studies analyzing
clinical outcomes are warranted.
Arrhythmias
Preliminary evidence suggests that RDN may have a salutary
effect in the management of recurrent arrhythmias in heart
failure patients, particularly those with atrial fibrillation
(Pokushalov et al., 2012) and ventricular tachycardia (Ukena
et al., 2012; Hoffmann et al., 2013), via a reduction in BP and
central sympathetic cardiac stimulation.
The potential antiarrhythmic efficacy of RDN was first
described in a normotensive porcine model (Linz et al., 2013a)
and canine with pacing-induced heart failure model (Zhao et al.,
2013). First-in-man experience comes from a small prospective
study of 27 patients with refractory symptomatic atrial fibrillation
and rHTN (Pokushalov et al., 2012). Compared to patients who
underwent usual treatment for atrial fibrillation pulmonary vein
isolation (PVI) (n = 14), patients who underwent a combined
therapy of PVI and RDN (n = 13) exhibited a two-fold reduction
in the occurrence of atrial fibrillation episodes (defined as <30 s
of atrial fibrillation during 9-months follow-up). Patients on
combined therapy also demonstrated a significant and sustained
BP reduction of −25/−10mmHg and reduction in LV mass
of approximately 10% at follow up. Findings from a two-study
meta-analysis suggest the salutary effects of RDNwhen used as an
adjunct therapy to PVI on atrial fibrillation reoccurrence is even
more pronounced in patients with severe rHTN (Pokushalov
et al., 2014). A recent study by McLellan et al. suggests
electrical remodeling, specifically an increase in global and atrial
conduction velocity, may in conjunction with structural changes
promote a reduction in atrial fibrillation reoccurrence following
RDN (McLellan et al., 2015).
Ventricular tachyarrhthmias (VTA) are associated with a
high, irregular heart rate (>100 bpm) and significant risk for
sudden death. Elevated cardiac sympathetic nerve activity has
been linked to the pathogenesis of VTAs (Meredith et al., 1991)
with structural changes in myocardial tissue (i.e., myocardial
hypertrophy and heart failure) caused by elevations in BP
thought to predispose patients to VTA (Anderson, 1984; Bryant
et al., 1999).
In a porcine model of acute coronary myocardial infarction,
RDN was shown to significantly reduce the incidence of
ventricular arrhythmia compared to a sham procedure (86 vs.
17%; p = 0.03) (Linz et al., 2013b). The efficacy of RDN
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to suppress ventricular tachycardia in adults has only been
explored in a few case studies involving patients with ventricular
electrical storm (Ukena et al., 2012; Hoffmann et al., 2013). Ukena
et al. reported the first-in-man experience in 2 patients suffering
from asymptomatic CHF (non-obstructive hypertrophic and
dilated cardiomyopathy, NYHA III) and treatment resistance
ventricular electrical storm (Ukena et al., 2012). In both patients,
RDN was shown to eliminate the occurrence of ventricular
tachyarrhythmic episodes at 6-months without altering BP. In
a 63 year old male with recurrent ventricular electrical storm
in the setting of acute myocardial infarction, the use of RDN
in combination with ventricular tachycardia catheter ablation
(standard therapy) was shown to eliminate both ventricular
tachycardia and ventricular fibrillation episodes at 23, 100,
and 160 days follow-up (Hoffmann et al., 2013). The patient
also experienced normalization of their BP, which warranted a
reduction in their antihypertensive medication.
While the observations reported in these case studies are
promising for RDN as an adjunctive therapy for patients with
serious cardiac electrical instability they underscore the need for
future randomized controlled trials.
Metabolic Diseases
Accumulating data from animal and human studies suggest
chronic sympathoexcitaion plays a pivotal role in the etiology
and complications of metabolic conditions. Even in the absence
of hypertension, elevated urinary noradrenaline levels, increased
efferent muscle sympathetic nerve activity, and elevated rates
of plasma noradrenaline spillover, are present in patients with
obesity, insulin resistance and the metabolic syndrome (Lee et al.,
2001; Grassi et al., 2005; Straznicky et al., 2008; Schlaich et al.,
2015).
Retrospective sub-cohort analyses of 37 rHTN patients who
underwent RDN in the Symplicity HTN-1 Study, showed
improvements in office BP (−32/−12mmHg; P < 0.001) were
accompanied by significant reductions in fasting plasma glucose,
insulin, C-peptide and 2-h post load glucose levels at 3-months
follow-up (all p > 0.04) (Mahfoud et al., 2011). Insulin sensitivity
as measured by the HOMA-IR and ISQUICKI index measures was
also improved by−62 and 13%, respectively, at 3-months follow-
up (both P = 0.001). Importantly, these beneficial metabolic
alterations were preserved in patients diagnosed with type 2
diabetes at baseline (n = 20). No BP or metabolic improvements
were reported in the control group (n = 13) who continued their
usual medication regime.
These impressive findings contrast with the recently published
Denervation of the Renal Artery in Metabolic Syndrome
(DREAMs) study that prospectively reported no effect of
RDN on measures of insulin sensitivity after 12-months in
29 patients with metabolic syndrome on ≤1 antihypertensive
and/or diabetic medication (Verloop et al., 2015). Of note, whole-
body sympathetic activity, as measured by microneurography
(n = 10), and heart rate variability (n = 26) did not change
at 12-months post-RDN despite a modest reduction in 24-h
ambulatory BP (mean change from baseline −6 ± 12/−5 ±
7mmHg; p < 0.02).
Improved glucose metabolism following RDN has been
reported in patients with polycystic ovary syndrome (Schlaich
et al., 2011) and obstructive sleep apnea (Witkowski et al., 2011),
two conditions that are characterized by multiple metabolic
disturbances. In 2 obese women with polycystic ovary syndrome,
RDNwas shown to lower fasting plasma glucose, improve insulin
sensitivity (assessed by euglycaemic hyperinsulinemic clamp)
and reduce both muscle sympathetic nerve activity and whole-
body noradrenaline spillover at 3-months follow-up (Schlaich
et al., 2011). Importantly, these metabolic effects were shown
to occur in the absence of any changes in body weight. In
10 patients with obstructive sleep apnea, RDN was associated
with improved 2-h glucose levels (median: 7.0 vs. 6.4mmol/L;
p = 0.05) during an oral glucose tolerance test and reduced
HbA1c levels (median: 6.1% vs. 5.6%; p < 0.05) at 6-months
follow-up (Witkowski et al., 2011). Improvements in office BP
(−34/−13mmHg: p < 0.01) and severity of obstructive sleep
apnoea for 80% of patients was also observed. Overall, the
evidence suggests acute improvements in insulin resistance and
glycemic control ensue from RDN. Understanding the longer
term effects of RDN in patients withmetabolic disease is expected
to be a focus for further investigation.
Future of Renal Denervation: Where to
from Here?
Despite the recent disappointment of Symplicity HTN-3, support
remains for the efficacy of RDN in the real world setting
(Bohm et al., 2015). Recent analyses from Medtronic’s Global
SYMPLICITY Registry showed 998 patients who underwent
RDN experienced a significant lowering in office and ambulatory
systolic BP by an average of−19.8 and−9.2mmHg, respectively,
after 6-months. For patients with a baseline systolic BP ≥
160mmHg, the BP reduction following RDN was even more
pronounced. The registry also confirmed the well-established
short-term safety profile of RDN with only six procedure-related
events reported (<1% of the cohort) during the 6-months.
Collectively, the results lend support to RDN being a safe and
viable therapeutic option in patients with severe rHTN when
traditional pharmacotherapy has failed.
In 2014, the Joint UK societies’ consensus statement on
RDN for rHTN called for a temporary moratorium on RDN
in routine clinical practice following the Symplicity HTN-3
announcement but was hesitant to abandon the therapy entirely,
citing the need for further research (Lobo et al., 2015). In
this respect, Symplicity HTN-3 has been invaluable in helping
guide the design and execution of future clinical studies. The
finding that patients who received ablations in all four quadrants
of the renal artery were more likely to experience significant
reductions in BP in Symplicity HTN-3 (Bhatt et al., 2014) coupled
with contemporary anatomical insights into the distribution of
renal artery nerves (Sakakura et al., 2014) demonstrates certain
ablation patterns are more efficacious for lowing BP than others.
Indeed, there is now a preferential shift toward the use of
modalities that circumferentially ablate nerves toward the distal
portion of both renal arteries. Patient selection is also critical
with meticulous identification of true treatment-rHTN using
ambulatory BP monitoring during a period of stable medication
(>8 weeks) confirmed by drug adherence testing necessary to
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eliminate patients without “neurogenic” hypertension and those
who simply are non-compliant with their BP medication.
At present, there is no intraprocedural marker to confirm
whether RDN has been successfully achieved. Instead, physicians
have naively relied on changes in BP to define procedural success.
Noradrenaline spillover testing has been performed in small sub-
groups of patients to quantify whole-body (Krum et al., 2009)
and renal sympathetic nerve activity (Esler, 2014a) prior to and
30-days post RDN. While a reduction in renal noradrenaline
spillover correlates with a reduction in BP, the response can
be highly variable between individual patients (Esler, 2014b).
Furthermore, the validated test is not suitable for use in large-
scale trials.
Identification of a novel biomarker of renal nerve injury that
can be measured in either urine or plasma immediately following
RDN would be the ne plus ultra to inform interventionists of
procedural success. Recent animal data suggests intraluminal
electrical stimulation of renal arteries pre- and post-RDN may
provide valuable insight in the acute efficacy of the procedure.
Indeed, Chinushi et al. reported an increase in BP, serum
catecholamines and heart rate variability immediately following
high-frequency electrical stimulation of renal arteries in a
hypertensive caninemodel, which was attenuated following RDN
(Chinushi et al., 2013). Adenosine infusion into the renal artery,
which under normal conditions potentiates a rise in BP, has also
been suggested as an immediate measure of renal afferent nerve
ablation success following RDN (Esler, 2014a).
Conclusion
Latest clinical trial data suggests RDN is a safe treatment
option in patients with true rHTN that is most efficacious
when used as an adjunct therapy to intensive pharmacotherapy.
It is hoped the development of next generation ablation
modalities that enable circumferential ablation coupled with
more stringent screening of true treatment rHTN will help
improve the clinical efficacy of RDN. Encouraging data from a
number of pre-clinical studies highlights that clinical benefits
beyond BP reduction can be gained following RDN in patients
with renal disease, heart failure, arrhythmias and metabolic-
related disease. However, caution is warranted not to over-
interpret the findings of these small studies with larger,
randomized controlled trials needed before the application of
RDN becomes routine in clinical practice for these patient
cohorts.
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